Piperazine pyridyl benzo[d] isoxazole derivatives and their synthesis thereof

Novel piperazine pyridyl benzo[d]isoxazole derivatives with specific substitutions address the limitations of existing benzisoxazole derivatives by providing enhanced therapeutic efficacy across multiple disease areas, including anticancer, antibacterial, antifungal, antiviral, anti-TB, anti-inflammatory, and antioxidant activities.

WO2026239156A1PCT designated stage Publication Date: 2026-11-19KURUMBALA ABDUL MAJEED +1
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
PCT/IB2025/057921
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2025-05-16
Filing Date
2025-08-04
Publication Date
2026-11-19

AI Technical Summary

Technical Problem

Existing benzisoxazole derivatives do not effectively address the potential for anticancer, antibacterial, antifungal, antiviral, anti-TB, anti-inflammatory, and antioxidant activities, and they have various drawbacks and limitations as therapeutic agents.

Method used

Development of novel piperazine pyridyl benzo[d]isoxazole derivatives with specific substitutions at the 3rd and 6th positions of the Benzisoxazole ring, synthesized through a multi-step process involving reactions such as coupling, carbamate formation, and diamine synthesis, to create compounds with enhanced therapeutic potential.

Benefits of technology

The novel compounds demonstrate effective anticancer, antibacterial, antifungal, antiviral, anti-TB, anti-inflammatory, and antioxidant activities, overcoming the limitations of previous derivatives and offering a cost-effective, safe, and practical therapeutic solution.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure IMGF000002_0001
    Figure IMGF000002_0001
  • Figure IMGF000002_0002
    Figure IMGF000002_0002
  • Figure IMGF000004_0001
    Figure IMGF000004_0001
Patent Text Reader

Abstract

The present invention relates to development of novel compounds of substituted Benzisoxazole derivatives. It particularly relates to the development of novel compounds of Heterocyclic derivatives containing substitution at 3rd and 6th position of Benzisoxazole ring. It specifically relates to the development of novel compounds of piperazine pyridyl benzo[d]isoxazole derivatives or pharmaceutically acceptable salt thereof as potential for anticancer, antibacterial, antifungal, antiviral, anti-microbial, anti-TB, anti-inflammatory, antioxidant etc. It also relates synthetic process for preparation of novel compounds of piperazine pyridyl benzo[d]isoxazole derivatives or pharmaceutically acceptable salt thereof. It further relates to the development of pharmaceutical composition or formulation with synthesized novel compounds of piperazine pyridyl benzo[d]isoxazole derivatives or pharmaceutically acceptable salt thereof. The newly synthesized compounds provide new approach to the development of biologically active compounds. Among the synthesized compounds, the preferred compounds are Compound 6, 8, & 11 which showed better Antibacterial, Antifungal and Antioxidant properties.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] PIPERAZINE PYRIDYL BENZO [d] ISOXAZOLE DERIVATIVES AND THEIR SYNTHESIS THEREOF

[0002] FIELD OF THE INVENTION

[0003] The present invention relates to development of novel compounds of substituted Benzisoxazole derivatives. It particularly relates to the development of novel compounds of Heterocyclic derivatives containing substitution at 3rdand 6thposition of Benzisoxazole ring. It specifically relates to the development of novel compounds of piperazine pyridyl benzo[d]isoxazole derivatives or pharmaceutically acceptable salt thereof as potential for anticancer, antibacterial, antifungal, antiviral, anti-microbial, anti-TB, anti-inflammatory, antioxidant etc. It also relates synthetic process for preparation of novel compounds of piperazine pyridyl benzo[d]isoxazole derivatives. It further relates to the development of pharmaceutical composition or formulation with synthesized novel compounds of piperazine pyridyl benzo [d]isoxazole derivatives or pharmaceutically acceptable salt thereof.

[0004] BACKGROUND OF THE INVENTION

[0005] Heterocyclic compounds exist either in natural or synthetic form and dominated as a source of biologically active compounds. The ease of synthesis process made the researchers to utilize the chemistry efficiently and to obtain the library of compounds to screen various biological activities. The usage and capability of these compounds in the biological system resembles the structure of peptides and reversibly bind to the proteins [1]. Among various heterocyclic compounds known to date, Isoxazole showed a promising role in most drug developments. Benzisoxazole and their derivatives contributed to the most Pharmacokinetics profiles. In recent developments the Benzisoxazole containing compounds interact with a wide range of spectrum of Protein Targets. Benzisoxazole compounds exhibits potential as anticancer, antibacterial, antifungal, antiviral, anti-microbial, anti-TB, anti-inflammatory, etc. Successful applications of developing Benzisoxazole compounds have resulted in multiple corresponding drugs in the market.

[0006] There are prior arts / reports which reported the benzisoxazole / benzoxazole derivatives and the interesting ones include the PCT publication no. WO2014120346 (U. S. A Patent family US9708308 B2) which discloses a compound of Formula (I)

[0007]

[0008] wherein A is a heterocycle ring system and B is a heterocycle ring system or aryl ring system, and pharmaceutical compositions comprising one or more of said compounds, and methods for using said compounds for treating or preventing thromboses, embolisms, hypercoagulability or fibrotic changes.

[0009] Another report, Lalut et.al, 2020 JLalut J, Payan H, Davis A, Lecoutey C, Legay R, Sopkova-de Oliveira Santos J. Claeysen S, Dallemagne P, Rochais C. Sei Rep. 2020 Feb 20; 10( l):3014. doi: 10.1038 / s41598-020-59805-7. PMID: 32080261; PMCID: PMC7033111] reported on the rational design of novel benzisoxazole derivatives with acetylcholinesterase inhibitory and serotoninergic 5-HT4 receptors activities for the treatment of Alzheimer's disease.

[0010] Another US patent no. US11548882B2 discloses a compound, a salt thereof, or a prodrug thereof as a compound effective for preventing and / or treating fibrosis, the compound being represented by formula (1)

[0011]

[0012] (wherein A is an optionally substituted benzene ring; B is optionally substituted aryl or optionally substituted heteroaryl; X is an oxygen atom or a sulfur atom; Y is a nitrogen atom or a carbon atom; of Y is a single or double bond when Y is a carbon atom, or of Y is a single bond when Y is a nitrogen atom; each R1 independently represents lower alkyl, or two Rls may be bound to each other to form a spiro ring or a crosslinked structure, or two Rls may be bound to each other to form a saturated fused heterocycle together with nitrogen and carbon atoms constituting a ring containing Y; p is 0, 1, or 2; or (Rl)p is oxo).

[0013] Another publication, Samanth & Bhat, 2025 [Samanth, M., & Bhat, M. (2025). Recent Developments in Chemistry and Biochemistry Research Vol. 10. 112-129. https: / / doi.org / 10.9734 / bpi / rdcbr / vi0 / 38091 reported that, the benzisoxazole s and their derivatives have been extensively investigated and applied across various medical fields. These compounds have demonstrated significant therapeutic potential in the management of cardiovascular conditions, including myocardial infarction, hypertension, and hyperlipidemia.

[0014] Additionally, they have been utilized in the treatment of inflammatory diseases, irritable disorders, and gastrointestinal conditions such as peptic ulcers. Benzisoxazoles also show promise in addressing metabolic disorders, including obesity, diabetes, and metabolic syndrome. Moreover, novel benzisoxazole derivatives exhibit a range of bioactive properties, including anti-inflammatory, anti-cancer, anti-glycation, and antibacterial activities. The continuous advancement in the development of highly active benzisoxazole-based compounds underscores their potential as scaffolds for future therapeutic candidates. Tills chapter focuses on the synthesis of benzisoxazole derivatives using various methodologies and highlights the significance of this pharmacophore in medicinal chemistry.

[0015] Another publication, Naidu et. al., 2014 [Naidu KM, Suresh A, Subbalakshmi J, Sriram D, Yogeeswari P, Raghavaiah P, Chandra Sekhar KV. Eur J Med Chem. 2014 Nov 24;87:71-8. doi: 10.1016 / j.ejmech.2014.09.043. Epub 2014 Sep 16. PMID: 25240097] reported on the synthesis of a series of twenty four novel 3-(4-(substitutedsulfonyl)piperazin-l- yl)benzo[d]isoxazole analogues and characterized using various spectroscopic techniques and evaluated for their in vitro anti-tubercular activity against Mycobacterium tuberculosis (MTB) H37Rv strain.

[0016] The review article, Shastri 2016 [Shastri, R. A. Chem Sci Trans 5 (2016): 8-20] reports that, 1,2-Benzisoxazole derivatives are oxygen, nitrogen containing heterocycles with wide range of synthetic and pharmaceutical applications, and are famous for biological activities. The high therapeutic properties of these heterocycles have encouraged the medicinal chemist to synthesize a large number of chemotherapeutic agents. 1, 2-Benzisoxazole derivatives can be synthesised by variety of methods, but the most popular method involves, the base catalysed cyclization of o- hydroxyl ketoximes or its derivatives.

[0017] Another publication, Lukoyanov et. al-Chapter 5 [Lukoyanov, Alexander A., Alexey Yu Sukhorukov, and Andrey A. Tabolin, " RECENT ADVANCES IN THE SYNTHESIS OF 1, 2- BENZISOXAZOLES AND 1, 2 -BENZISOXAZOLINES. " Chapter 5 DOI: http: / / dx.medra.org / 10. 7374 / targets.2025.28.67] reported that, 1,2-benzisoxazole core is present in natural alkaloids and is used as a versatile building block m drug discovery because of the wide range of pharmacological activities. 1,2-Benzisoxazole-containing drugs such as zonisamide and risperidone have been used as anticonvulsants for decades. Although old synthetic methods for benzisoxazole core synthesis were efficient enough, development of organic chemistry inevitably led to the emerging of new approaches to this heterocycle moiety. This review covers classical and modem synthetic approaches to 1,2-benzisoxazoles, 1,2- benzisoxazolines and benzisoxazoline-3-ones that have been used in the last 25 years.

[0018] Another review on Patent publications from 2009 to 2014 by Uto Y, 2015 [Uto, Y. (2015).

[0019] Expert Opinion on Therapeutic Patents, 25(6), 643-662.

[0020] reported that, more recent examples of

[0021]

[0022] structural modification of existing drugs led to the discovery of some promising benzisoxazoles for antipsychotic use. The design of multi -target ligands is important for the manipulation of pharmacological properties and safety profiles for the use of antipsychotics. Benzisoxazoles have been widely used as pharmacophores in the search for novel drug candidates in a variety of therapeutic area. It is fair to assume that the wide and frequent use of benzisoxazoles in drug discovery and development will continue into the future.

[0023] Though there prior art reports which reported the different benzisoxazoles compounds and their derivatives or pharmaceutically acceptable salt thereof as therapeutic agents but none of the prior arts in the literature reported or disclosed the novel compounds of Heterocyclic derivatives containing substitution at 3rd and 6th position of Benzisoxazole ring and specifically novel compounds of piperazine pyridyl benzo[d]isoxazole derivatives or pharmaceutically acceptable salt thereof as potential for anticancer, antibacterial, antifungal, antiviral, anti-microbial, anti-TB, anti-inflammatory, antioxidant along with not having the drawbacks or limitations of the prior art or existing compounds. There exists several drawbacks or limitations with the prior art compounds to act as therapeutic agents. Therefore, the present inventors have developed the novel compounds of Heterocyclic derivatives containing substitution at 3rd and 6th position of Benzisoxazole ring and specifically novel compounds of piperazine pyridyl benzo[d]isoxazole derivatives or pharmaceutically acceptable salt thereof as potential for anticancer, antibacterial, antifungal, antiviral, anti-microbial, anti-TB, antiinflammatory, antioxidant along with the developed compounds not having the drawbacks or limitations of the prior art or existing compounds. The invention also includes the development of suitable method for synthesis of novel compounds of substituted Benzisoxazole derivatives or pharmaceutically acceptable salt thereof.

[0024] OBJECTS OF THE INVENTION

[0025] The primary object of the present invention is the development of novel compounds of substituted Benzisoxazole derivatives.

[0026] The particular object of the present invention is the development of novel compounds of Heterocyclic derivatives containing substitution at 3rdand 6thposition of Benzisoxazole ring.

[0027] The specific object of the present invention is the development of novel compounds of piperazine pyridyl benzo[d]isoxazole derivatives or pharmaceutically acceptable salt thereof as potential for anticancer, antibacterial, antifungal, antiviral, anti-microbial, anti-TB, antiinflammatory, antioxidant etc.

[0028] The other object of the present invention is the development of synthetic process for preparation of novel compounds of piperazine pyridyl benzo [d]isoxazole derivatives or pharmaceutically acceptable salt thereof.

[0029] The other objective of the present invention is to synthesize l-(3-bromophenyl)-4- m ethylpiperazine using 2,6-dibromo pyridine coupling with N-Methyl piperazine.

[0030] The other objective of the present invention is to keep the fixed substitution at 3 position of the Benzisoxazole amine by utilizing Buchwald condition.

[0031] The other object of the present invention is the development of pharmaceutical composition or formulation with synthesized novel compounds of piperazine pyridyl benzo [d]isoxazole derivatives or pharmaceutically acceptable salt thereof.

[0032] The other object of the present invention is the development of piperazine pyridyl benzo [d]isoxazole derivatives or pharmaceutically acceptable salt thereof which are effective in treatment of several diseases and cost-effective.

[0033] The other object of the present invention is the development of piperazine pyridyl benzo [d]isoxazole derivatives or pharmaceutically acceptable salt thereof which are easy to use with little technical expertise.

[0034] The other object of the present invention is the development of piperazine pyridyl benzo [d]isoxazole derivatives or pharmaceutically acceptable salt thereof which are safe and practical to use.

[0035] STATEMENT OF THE INVENTION

[0036] A compound of Formula I:

[0037]

[0038] Formula I

[0039] or pharmaceutically acceptable salt thereof, wherein

[0040] R is independently selected from hydrogen, halogen, -CN, -NH2, -OH, -NO2, alkyl, alkenyl, haloalkyl, cyanoalkyl, hydroxyalkyl, haloalkoxy, alkoxy, alkylamino, aminoalkyl, and cycloalkyl and a heterocycloalkyl.

[0041] The R is selected from the group consisting of:

[0042]

[0043] The compound selected from the group consisting of:

[0044]

[0045]

[0046] A pharmaceutical composition or formulation comprising the compound of Formula I or pharmaceutically acceptable salt thereof and pharmaceutically acceptable excipients or carriers.

[0047] A process for synthesis of compound of formula I comprising:

[0048] (i) synthesis of tert-butyl 4-cyano-3 -fluorophenylcarbamate by reacting 4- amino-2 -fluorobenzonitrile with tetrahydrofuran in presence of N, N- Diisopropylethylamine;

[0049] (ii) then converting the tert-butyl 4-cyano-3 -fluorophenylcarbamate obtained in step (i) into tert-butyl 3-aminobenzo[d]isoxazol-6- ylcarbamate by reacting with N-hydroxyacetamide in presence of dimethylformamide and K₂CO₃;

[0050] (iii) then tert-butyl 3-aminobenzo[d]isoxazol-6-ylcarbamate obtained in step (ii) is reacted with with l-(6-bromopyridin-2-yl)-4-methylpiperazine in presence of 1,4-Dioxane, K2CO3, Xantphos to get tert-butyl 3-(6-(4- methylpiperazin-l-yl)pyridin-2-ylamino)benzo[d]isoxazol-6- ylcarbamate;

[0051] (iv) then the tert-butyl 3-(6-(4-methylpiperazin-l-yl)pyridin-2- ylamino)benzo[d]isoxazol-6-ylcarbamate obtained in step (iii) is stirred with 1,4-Dioxane to get N3-(6-(4-methylpiperazin-l-yl)pyridin-2- yl)benzo [d] isoxazole -3, 6-diamine;

[0052] (v) then finally the N3-(6-(4-methylpiperazin-l-yl)pyridin-2- yl)benzo[d]isoxazole-3, 6-diamine obtained in step (iv) is reacted with either Hexafluorophosphate Azabenzotriazole Tetramethyl Uranium or Mesylchloride in presence of N, N-Diisopropylethylamine and dimethylformamide to get the compound of Formula I

[0053] l-(6-bromopyridin-2-yl)-4-methylpiperazine is synthesized by the reaction of 2,6-dibromopyridine with 1 -methylpiperazine in presence of dimethylformamide and K₂CO₃.

[0054] DETAILED DESCRIPTION OF THE INVENTION

[0055]

[0056] Examples:

[0057] Synthesis of tert-butyl 4-cyano-3-fluorophenylcarbamate (2):

[0058] To a stirred solution of 4-amino-2 -fluorobenzonitrile (1 eq) in dry tetrahydrofuran [THF] (10 vol) taken in a single neck RB flask was added N, N-Diisopropylethylamine [DIPEA] (3 eq) and stirred the reaction mixture for 10 min at rt. Added Boc Anhydride (2 eq) followed by 4- Dimethylaminopyridine [DMAP] (0.1 eq) and continued stirring the reaction mixture for 16h. The reaction progress was monitored using TLC (20% EtOAc in hexanes). After completion of the reaction, water was added and extracted the reaction mixture with Ethylacetate (50 mL X 2) times. The organic layer was separated, dried over Na2SO4 and evaporated under reduced pressure. The crude product obtained was purified using flash chromatography on silica gel (EtOAc / hexane 1:1) to get tert-butyl 4-cyano-3 -fluorophenylcarbamate as off white solid.

[0059] Synthesis of tert-butyl 3-aminobenzo[d]isoxazol-6-ylcarbamate (3):

[0060] To a stirred solution of tert-butyl 4-cyano-3 -fluorophenylcarbamate (1 eq) in dry dimethylformamide [DMF] (10 vol) taken in a single neck RB flask at was added K2CO3 (3eq) andN-hydroxyacetamide (3 eq). The reaction mixture was stirred at rt for 16h. The reaction progress was monitored using TLC (20% EtOAc in hexanes). After completion of the reaction, water was added and extracted the reaction mixture with Ethylacetate (50 mL X 2) times. The organic layer was separated, dried over Na2SO4 and evaporated under reduced pressure. The crude product obtained was purified using flash chromatography on silica gel (EtOAc / hexane 1:1) to get tert-butyl 3-aminobenzo[d]isoxazol-6-ylcarbamate as white solid.

[0061] Synthesis of l-(6-bromopyridin-2-yl)-4-methylpiperazine (5):

[0062] To a stirred solution of 2,6-dibromopyridine (1 eq) in dry DMF (10 vol) taken in a single neck RB flask was added K2CO3 (3 eq) and 1 -methylpiperazine (1.2 eq) at rt. The reaction mixture was stirred at rt for 16h. The reaction progress was monitored using TLC (20% EtOAc in hexanes). After completion of the reaction, water was added and extracted the reaction mixture with Ethylacetate (50 mL X 2) times to get l-(6-bromopyridin-2-yl)-4-methylpiperazine as a light brown liquid.

[0063] Synthesis of tert-butyl 3-(6-(4-methylpiperazin-l-yl)pyridin-2-ylamino)benzo[d]isoxazol-6-ylcarbamate (6):

[0064] To a stirred solution of tert-butyl 3-aminobenzo[d]isoxazol-6-ylcarbamate (1 eq) in dry 1,4-Dioxane (20mL) taken in a single neck RB flask was added l-(6-bromopyridin-2-yl)-4-methylpiperazine (1.2 eq), K2CO3 (3 eq) and Xantphos (0.2 eq). Pd2(dba)3 (0.05 eq) was added under argon and heated the reaction mixture to 90°C for 16h. The reaction progress was monitored using TLC (10% MeOH in DCM). After completion of the reaction, water was added and extracted the reaction mixture was extracted with 10% MeOH in DCM (30 mL X 2) times. The organic layer was separated, dried over Na2SO4 and evaporated under reduced pressure. The crude product obtained was purified using flash chromatography on silica gel (MeOH / DCM 1:1) to get tert-butyl 3-(6-(4-methylpiperazin-l-yl)pyridin-2-ylamino)benzo[d]isoxazol-6-ylcarbamate as a light brown solid.

[0065] Synthesis of N3-(6-(4-methylpiperazin-l-yl)pyridin-2-yl)benzo[d]isoxazole-3,6-diamine

[0066] (7):

[0067] To a stirred solution of tert-butyl 3-(6-(4-methylpiperazin-1-yl)pyridin-2-ylamino)benzo[d]isoxazol-6-ylcarbamate (1 eq) in dry 1,4-Dioxane (10 mL) taken in a single neck RB flask was added 4N Dioxane.HCl and stirred the reaction mixture at rt for 2h to get N3-(6-(4-methylpiperazin-l-yl)pyridin-2-yl)benzo[d]isoxazole-3,6-diamine.

[0068] Synthesis of Methanesulfonyl N3-(6-(4-methylpiperazin-l-yl)pyridin-2-yl)benzo [d] isoxazole-3,6-diamine (91):

[0069] To a stirred solution of N3-(6-(4-methylpiperazin-l-yl)pyridin-2-yl)benzo[d]isoxazole-3,6-diamine (1 eq) in DMF(1 mL) was added DIPEA (2.0 eq) and Mesylchloride (1.5 eq) and stirred the reaction mixture at rt for 16h. The reaction progress was monitored using TLC (20% EtOAc in Hexane). After completion of the reaction, water was added and extracted the reaction mixture with ethylacetate (10 mL X 2) times. The organic layer was separated, dried over Na2SO4 and evaporated under reduced pressure. The crude product obtained was purified using flash chromatography on silica gel (MeOH / DCM 1: 1) to get Methane sulfonyl N3-(6-(4-methylpiperazin- 1 -yl)pyri din-2 -yl)benzo[d]isoxazole-3,6-diamine.

[0070] General procedure for the synthesis of Amide Derivatives 8(a-k):

[0071] To a stirred solution of N3-(6-(4-methylpiperazin-l-yl)pyridin-2-yl)benzo[d]isoxazole-3,6-diamine (1 eq) in DMF(1 mL) was added corresponding acids (2.0 eq), Hexafluorophosphate Azabenzotriazole Tetramethyl Uronium [HATU] (2.0 eq) and DIPEA (3.0 eq) and stirred the reaction mixture at rt for 16h. The reaction progress was monitored using TLC (10% MeOH in DCM). After completion of the reaction, water was added and extracted the reaction mixture was extracted with 10% MeOH in DCM (30 mL X 2) times. The organic layer was separated, dried over Na2SO4 and evaporated under reduced pressure. The crude product obtained waspurified using flash chromatography on silica gel (MeOH / DCM 1:1) to get the Amide Derivatives.

[0072] Int-2

[0073]

[0074] ¹H NMR (300 MHz, DMSO-d₆) δ ppm 1.49 (s, 9H) 2.29 (s,3H) 2.60 (br s, 4H) 3.49(br s, 4H) 6.66 (d, J=6.82Hz,1H) 7.11 (dd, J=8.62,2.15Hz,1H) 7.21 (d, J=2.15Hz,1H) 7.46 (dd, J=8.80, 0.90Hz, 1H) 7.69 (dd, J=8.62, 7.90Hz,1H) 7.99 (d, J=8.62Hz,1H) 9.55 (s,1H) 11.45 (s,1H).

[0075]

[0076]

[0077] ¹H NMR (300 MHz, DMSO-d₆) δ ppm 1.70 (br dd, J= 9.51, 3.77Hz, 5 H) 2.44 (br d, J=6.10 Hz, 3H) 2.56 - 2.67 (m, 1 H) 2.70 - 2.98 (m, 4 H) 3.17(d, J=5.03 Hz, 2 H) 3.47 - 3.66 (m, 4 H) 3.85 - 3.98 (m, 2 H) 6.70 (d, J=7.18 Hz, 1 H) 7.21(dd, J=8.62, 2.15 Hz, 1 H) 7.38 - 7.58 (m, 2 H) 7.71 (t, J=8.08 Hz, 1 H) 8.05 (d, J=8.62 1 H) 10.05 (s, 1 H) 11.50 (s, 1 H)

[0078]

[0079] LCMS (M+l 409).

[0080] Comp 6

[0081]

[0082] ¹H NMR (300 MHz, DMSO-d₆) δ ppm 2.36 (s, 3 H) 2.70 (br s, 4 H) 3.54 (br s,4 H) 6.70 (d, J=7.90 Hz, 1 H) 7.51 (d, J=8.62 Hz, 1 H) 7.60 (dd, J=8.62, 1.80 Hz, 1 H) 7.67 - 7.79 (m, 2 H) 8.12 (d, J=8.62 Hz, 1 H) 8.32 (d, J=8.26 Hz, 1 H) 8.60 (dd, J=8.26, 2.15 Hz, 1 H) 9.22 (d, J=1.44 Hz, 1 H)10.93 (s, 1 H) 11.58 (s,1 H)

[0083] LCMS (M+l 455).

[0084] Comp 8

[0085]

[0086] ¹HNMR (300 MHz, DMSO-d₆) δ ppm 2.05 - 2.17 (m, 4 H) 2.21 - 2.29 (m, 2 H) 2.83 (br s, 4 H) 3.54 -3.60 (m, 1 H) 3.56 (br s, 3 H) 6.70 (d, J=7.90Hz, 1 H) 7.20 (dd, J=8.62, 1.80 Hz, 1 H) 7.43 - 7.49 (m, 2 H) 7.65 - 7.76 (m, 1 H) 8.04 (d, J=8.62 Hz,1 H) 9.89 (s, 1 H) 11.49 (s, 1 H) LCMS (M+1 407).

[0087]

[0088] ¹H NMR (300 MHz, DMSO-d₆) δ ppm 1.94 (br d, J=11.13 Hz, 4 H) 2.07

[0089] - 2.16 (m, 4 H) 2.36 (s, 3 H) 2.69 (br s, 5 H) 3.50 - 3.56 (m, 4H) 6.68 (d,

[0090] J=7.54 Hz, 1 H) 7.22 (br d, J=1.44 Hz, 1 H) 7.42 - 7.48 (m, 2H) 7.69 (d, J=7.90 Hz, 1 H) 8.04 (d, J=8.62 Hz, 1 H) 10.12 (s, 1 H)11.51 (s, 1 H)

[0091] LCMS (M+l 471).

[0092] Comp 10

[0093]

[0094] ¹HNMR (300 MHz DMSO-d₆) ) δ ppm 1.19 - 1.30 (m, 2 H) 1.70 (br t, J=11.31 Hz, 4 H) 1.82 - 1.94 (m, 2H) 2.39 (br s, 3 H) 2.74 (br s, 5 H) 3.54 (br s, 4 H) 6.69 (br d, J=7.54Hz, 1 H) 7.20 (dd, J=8.62, 1.44 Hz, 1 H) 7.43 - 7.51 (m, 2 H)7.64 - 7.76 (m, 1 H) 8.04 (d, J=8.62 Hz, 1 H) 10.03 (s, 1H) 11.49 (br s, 1 H).

[0095] LCMS (M+l 421).

[0096] Comp 12

[0097]

[0098] ¹HNMR (300 MHz, DMSO-d₆) δ ppm 2.39 (br s, 3 H) 2.74 (br s, 5 H)

[0099] 3.19 (s, 3 H) 3.54 (br s, 4 H) 6.69 (br d, J=7.54 Hz, I H) 7.20

[0100] (dd, J=8.62,1.44 Hz, 1 H) 7.43 - 7.51 (m, 2 H) 7.64 - 7.76 (m, 1 H) 8.04 (d, J=8.62 Hz, 1 H) 10.03 (s,1H) 11.49 (br s,1H).

[0101] LCMS (M+l 403).

[0102] Biological Screening

[0103] (a) Antibacterial Activity: All the compounds were tested against 6 bacterial strains viz. Staphylococcus aureus (ATCC 11632, Sa), Streptococus faecalis (ATCC 14506, Sf), Bacillus subtilis (ATCC 60511, Bs), Klebsiella pneumoniae (ATCC 10031, Kp), Escherichia coli (ATCC 10536, Ec), and Pseudomonas aeruginosa (ATCC 15442, Sa).

[0104] A 20 mL of the agar medium was poured into each petri dish containing antibacterial strains by the serial plate dilution method. The plates were dried at 37° C for one hour by using an incubator. The test compounds were diluted with dimethyl sulphoxide and added to the petri dish. The plates were then kept for 3-4 days at 37° C. The activity of each compound was measured by using standard Ciprofloxacin. The average readings were taken with variable concentrations at 1.56 pg / mL, 6.25 pg / mL, 12.5 pg / mL and 25 pg / mL. The zone of inhibition and MIC (Minimal Inhibitory Concentration) values of all the compounds were recorded in Table 1.

[0105] (b) Antifungal Activity: The newly synthesized compounds were screened for their antifungal activities against two strains of fungi Saccharomyces cerevisiae (ATCC 9763, Sc) and Candida tropicalis (ATCC 1369, Ct), mould: Aspergillus niger (ATCC 6275, An) by serial plate dilution method.

[0106] An agar medium was poured into each petri dish containing fungal stains. After which the plates were placed in an incubator at 37° C for an hour. Testing compounds were added to the petri dish by dissolving in dimethyl sulphoxide and kept for 3-4 days at 37° C. The antifungal activities of each compound were measured with the Fluconazole as a standard. The zone of inhibition for each compound was measured and the results are summarized in Table 1.

[0107] (c) Antioxidant Activity: Compounds with different concentrations of solutions (10 pM, 25 pM, 50 pM, 100 pM) were prepared by serial dilution method and the free radical scavenging activity was studied. The 2,2-diphenyl-l-picrylhydrazyl (DPPH) scavenging activity was carried out according to Blois method. The compound with different concentrations was taken in a test tube. A 4 mL of 0.1mM ethanol solution of DPPH was added and shaken vigorously. The test tubes under study were kept in a dark room for 20 minutes at room temperature. A change in absorbance was recorded against DPPH blank which was prepared without the compound in ethanol. The absorbance was recorded under UV-visible spectrometer at 517 nm for the remaining DPPH. The percentage decrease in the absorbance for each concentration was calculated based on the observed decrease in the absorbance of the radical.

[0108] The percentage of inhibition was calculated using the following equation.

[0109] Radical Scavenging Activity (RSA) (%) = [(A₀-A₁) / A₀ x 100]

[0110] where, A₀ is the absorbance of the control (blank, without compound), A₁ is the absorbance of the compound.

[0111] Hydrogen peroxide is generated in vivo by several oxidase enzymes. There is increasing evidence that hydrogen peroxide, either directly or indirectly via its reduction product [hydroxy radical (OH-)] causes severe damage to the biological system. In this method, when a scavenger is incubated with hydrogen peroxide, the decay or loss of hydrogen peroxide can be measured spectrophotometrically at 230 nm. A solution of hydrogen peroxide (20 mM) was prepared in phosphate-buffered saline (PBS) at pH 7.4. Various concentrations of 1 ml of the extracts or standards in methanol were added to 2 ml of hydrogen peroxide solutions in phosphate buffer saline. The absorbance was measured at 230 nm, after 10 min.

[0112] The scavenging activity of compounds was evaluated for DPPH and H₂O₂ radical scavenging potency. In compounds expressed in Table 2 were found to exhibit least-to-moderate antioxidant activity.

[0113] Table 1: Antimicrobial activity expressed as MIC (pg / mL),

[0114]

[0115] Table 2: Scavenging activities

[0116]

Claims

We Claim,Formula Ior pharmaceutically acceptable salt thereof, whereinR is independently selected from hydrogen, halogen, -CN, -NH2, -OH, -NO2, alkyl, alkenyl, haloalkyl, cyanoalkyl, hydroxyalkyl, haloalkoxy, alkoxy, alkylamino, aminoalkyl, and cycloalkyl and a heterocycloalkyl.

2. The compound of Formula I as claimed in claim 1 wherein the R is selected from the group consisting of:

3. The compound of Formula I as claimed in claim 1 or 2 wherein the compound selected from the group consisting of:

4. The compound of Formula I as claimed in any of the claims 1 to 3 wherein the compound preferably selected is5. The compound of Formula I as claimed in any of the claims 1 to 3 wherein the compound preferably selected is6. The compound of Formula I as claimed in any of the claims 1 to 3 wherein the compound preferably selected is7. A pharmaceutical composition or formulation comprising the compound of Formula I or pharmaceutically acceptable salt thereof as claimed in any of the claim 1 to 6 and pharmaceutically acceptable excipients or carriers.

8. A process for synthesis of compound of formula I as claimed in claim 1 comprising:(i) synthesis of tert-butyl 4-cyano-3 -fluorophenylcarbamate by reacting 4-amino-2- fluorobenzonitrile with tetrahydrofuran in presence of N, N- Diisopropylethylamine;(ii) then converting the tert-butyl 4-cyano-3 -fluorophenylcarbamate obtained in step (i) into tert-butyl 3-aminobenzo[d]isoxazol-6-ylcarbamate by reacting with N- hydroxyacetamide in presence of dimethylformamide and K₂CO₃;(iii) then tert-butyl 3-aminobenzo[d]isoxazol-6-ylcarbamate obtained in step (ii) is reacted with with l-(6-bromopyridin-2-yl)-4-methylpiperazine in presence of1,4-Dioxane, K2CO3, Xantphos to get tert-butyl 3-(6-(4-methylpiperazin-l- yl)pyridin-2-ylamino)benzo[d]isoxazol-6-ylcarbamate;(iv) then the tert-butyl 3-(6-(4-methylpiperazin-l-yl)pyridin-2- ylamino)benzo[d]isoxazol-6-ylcarbamate obtained in step (iii) is stirred with 1,4- Dioxane to get N3-(6-(4-methylpiperazin-l-yl)pyridin-2-yl)benzo[d]isoxazole- 3,6-diamine;(v) then finally the N3-(6-(4-methylpiperazin-l-yl)pyridin-2-yl)benzo[d]isoxazole-3,6-diamine obtained in step (iv) is reacted with Hexafluorophosphate Azabenzotriazole Tetramethyl Uronium or Mesylchloride in presence of N, N- Diisopropylethylamine and dimethylformamide to get the compound of Formula IFormula Iwherein R is independently selected from hydrogen, halogen, -CN, -NH2, -OH, -NO2, alkyl, alkenyl, haloalkyl, cyanoalkyl, hydroxyalkyl, haloalkoxy, alkoxy, alkylamino, aminoalkyl, and cycloalkyl and a heterocycloalkyl.

9. The process for synthesis of compound of formula I as claimed in claim 8 wherein 1- (6-bromopyridin-2-yl)-4-methylpiperazine is synthesized by the reaction of 2,6- dibromopyridine with 1 -methylpiperazine in presence of dimethylformamide and K₂CO₃.

10. The process for synthesis of compound of formula I as claimed in claim 8 wherein the synthesized compound is selected from the group consisting of: